United Therapeutics jumped more than 12% in pre-market trading on March 30 after positive TETON-1 trial data. The data prompted price-target increases from two major Wall Street firms, driving a significant company-specific rally and signaling upgraded analyst sentiment toward the stock.
United Therapeutics jumped more than 12% in pre-market trading on March 30 after positive TETON-1 trial data. The data prompted price-target increases from two major Wall Street firms, driving a significant company-specific rally and signaling upgraded analyst sentiment toward the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
